According to documents submitted to the SEC, biotechnology company Avai Bio Inc and Ainnova Tech have agreed, as of May 7, 2026, to jointly terminate their previously established joint venture and related licensing agreements.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Regency Centers posts updated investor presentation on website
To broaden financing channels for massive AI investment, Meta (META.US) reaches out to European bond investors and may enter the non-dollar bond market for the first time.
As the artificial intelligence boom drives continued capital expenditure growth among major tech companies, tech giants are increasingly turning to various global bond markets to seek financing sources.
Cosmos Health Unit Enters 5-Year Contract Manufacturing Deal With Viofar Over Cardiovascular Medicine
